Straits Times Index
3,262.44 -2.09 (-0.06%) Nikkei
38,073.98 -128.39 (-0.34%) Hang Seng
18,524.78 +210.92 (+1.15%) FTSE 100
8,358.55 +4.50 (+0.05%) Bitcoin USD
61,494.96 -710.20 (-1.14%) CMC Crypto 200
1,310.84 +10.74 (+0.83%)
ERAS May 2024 5.000 call
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 5.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswireErasca Reports First Quarter 2024 Business Updates and Financial Results
Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors Pro forma cash, cash equivalents, and marketable securities of $334 million is expected to fund operations into H2 2026 SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discover
GlobeNewswireErasca to Present at the Bank of America Health Care Conference
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will present on Wednesday, May 15, 2024 at 4:20 pm Pacific Time and will also participate in one-on-one investo
- GlobeNewswire
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer Poster presentations will feature SEACRAFT-1 Phase 1 trial design for naporafenib plus trametinib in RAS Q61X mutations, and preliminary FLAGSHP-1 Phase 1 results for ERAS-601 and cetuximab in chordoma SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused
